Mostrar el registro sencillo del ítem

dc.contributor.authorLuque Navarro, Pilar María
dc.contributor.authorCarrasco Jiménez, María Paz 
dc.contributor.authorGoracci, Laura
dc.contributor.authorParedes Martínez, José Manuel 
dc.contributor.authorEspinar Barranco, Laura
dc.contributor.authorValverde Pozo, Javier 
dc.contributor.authorTorretta, Archimede
dc.contributor.authorParisini, Emilio
dc.contributor.authorMariotto, Elena
dc.contributor.authorMarchioro, Chiara
dc.contributor.authorLaso, Alejandro
dc.contributor.authorMarco De La Calle, Carmen 
dc.contributor.authorViola, Giampietro
dc.contributor.authorLanari, Daniela
dc.contributor.authorLópez Cara, Luisa Carlota 
dc.date.accessioned2025-02-03T11:02:54Z
dc.date.available2025-02-03T11:02:54Z
dc.date.issued2023
dc.identifier.citationPublished version: Pilar M. Luque-Navarro et al. New bioisosteric sulphur-containing choline kinase inhibitors with a tracked mode of action. European Journal of Medicinal Chemistry 2023, 246, 115002; doi: 10.1016/j.ejmech.2022.115003es_ES
dc.identifier.urihttps://hdl.handle.net/10481/101891
dc.descriptionThis research was funded by Convocatoria 2019 Proyectos de I + D + i − RTI Tipo B “Ministerio de Innovación y Ciencia” [grant number PID2019-109294RB-I00] and “Convocatoria 2020 Proyectos I + D + i del Programa Operativo FEDER 2020”, [grant number B-CTS-216-UGR20]. E.P. thanks the ERDF project BioDrug [No. 1.1.1.5/19/A/004] and the Latvian Council of Science [grant number lzp-2020/2-0013] for financial support.es_ES
dc.description.abstractSince the identification of human choline kinase as a protein target against cancer progression, many compounds have been designed to inhibit its function and reduce the biosynthesis of phosphatidylcholine. Herein, we propose a series of bioisosteric inhibitors that are based on the introduction of sulphur and feature improved activity and lipophilic/hydrophilic balance. The evaluation of the inhibitory and of the antiproliferative properties of the PL (dithioethane) and FP (disulphide) libraries led to the identification of PL 48, PL 55 and PL 69 as the most active compounds of the series. Docking analysis using FLAP suggests that for hits to leads, binding mostly involves an interaction with the Mg2+ cofactor, or its destabilization. The most active compounds of the two series are capable of inducing apoptosis following the mitochondrial pathway and to significantly reduce the expression of anti-apoptotic proteins such as the Mcl-1. The fluorescence properties of the compounds of the PL library allowed the tracking of their mode of action, while PAINS (Pan Assays Interference Structures) filtration databases suggest the lack of any unspecific biological response.es_ES
dc.description.sponsorshipMinisterio de Innovación y Ciencia [PID2019-109294RB-I00]es_ES
dc.description.sponsorshipFEDER 2020 [B-CTS-216- UGR20]es_ES
dc.description.sponsorshipERDF [No. 1.1.1.5/19/A/004]es_ES
dc.description.sponsorshipLatvian Council of Science [lzp-2020/2-0013]es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAntitumoral druges_ES
dc.subjectCholine kinase inhibitiones_ES
dc.subjectBioisosterismes_ES
dc.subjectEnvironmental synthesises_ES
dc.titleNew bioisosteric sulphur-containing choline kinase inhibitors with a tracked mode of actiones_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.ejmech.2022.115003
dc.type.hasVersionSMURes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional